Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Metformin  COVID-19 treatment studies for Metformin  C19 studies: Metformin  Metformin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes
Petakh et al., Medical Archives, doi:10.5455/medarh.2022.76.329-332
Petakh et al., Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes, Medical Archives, doi:10.5455/medarh.2022.76.329-332
Oct 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Analysis of hematologic parameters in COVID-19 patients with diabetes in Ukraine, showing significantly lower CRP for patients taking metformin.
Petakh et al., 1 Oct 2022, retrospective, Ukraine, peer-reviewed, median age 62.7, 6 authors, study period January 2022 - March 2022.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMetforminAll
Abstract: Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes ORIGINAL PAPER doi: 10.5455/medarh.2022.76.329-332 MED ARCH. 2022 OCT; 76(5): 329-332 RECEIVED: JUL 04, 2022 ACCEPTED: AUG 10, 2022 Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, Ternopil, Ukraine 1 2 Department of Biochemistry and Pharmacology, Uzhhorod National University, Uzhhorod, Ukraine Uzhhorod, Ukraine 3 Department of Internal Diseases, Uzhhorod National University, Uzhhorod, Ukraine 4 5 Transcarpathian Regional Clinical Infectious Hospital, Uzhhorod, Ukraine Corresponding author: Pavlo Petakh, MD. Department of Microbiology, Virology, and Immunology, I. Horbachevsky Ternopil National Medical University, 46001 Ternopil, Ukraine. E-mail: pavlo@gmail. com. ORCID ID: http//www.orcid.org/00000002-0860-4445. Effects of Metformin, Insulin on Hematological Parameters of COVID-19 Patients with Type 2 Diabetes Pavlo Petakh1,2, Vasilij Griga2, Issah Bin Mohammed3, Kateryna Loshak4, Ivan Poliak5, Aleksandr Kamyshnyiy1 ABSTRACT Background: COVID-19 infection caused by SARS-COV-2 can result in multi-organ injuries and significant mortality in severe and critical patients, particularly those with type 2 diabetes as a comorbidity. Metformin and insulin are the main diabetes medications that affect the outcome of patients with COVID-19. Objective: The purpose of our study was to find out the features of the hematological indicators of patients with COVID-19 patients and type 2 diabetes. Methods: This is a retrospective study of the hospital confirmed COVID-19 patients between January to March 2022, who were admitted to Transcarpathian Regional Clinical Infectious Diseases Hospital (Uzhhorod, Ukraine). Results: The effect of type 2 diabetes, metformin, and insulin on COVID-19 were analyzed, respectively. Demographics and blood laboratory indices were collected. In patients who took metformin, the level of CRP was significantly lower than in patients who did not take metformin (24 mg/L [IQR 15 - 58] vs 52 mg/L, [IQR 22–121], P = 0.046). Conclusion: Our findings suggest that pre-admission metformin use may benefit COVID-19 patients with type 2 diabetes. Keywords: COVID-19, diabetes, metformin, insulin. 1. BACKGROUND Coronavirus disease 2019 (COVID‐19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS‐CoV‐2), was first reported in December 2019 (1, 2). The severity of COVID-19 ranges from asymptomatic to severe infection leading to death (1). Diabetes is a chronic disease that affects over 463 million people around the world (3). Studies reported that 20–50% of COVID-19 patients have diabetes depending on different areas (4). Also diabetic patients with COVID-19 had poorer prognosis compared to non-diabetic patients (5-7). The diabetes medication regimen may have influenced the progression (8, 9). The most commonly used diabetes medications are metformin and insulin. Theoretical evidence suggests that metformin may be beneficial for reducing proinflammatory and profibrotic states (2, 10, 11) and improving immune response (12). Insulin treatment may increase the risk of poor prognosis by increasing renal Angiotensin Converting Enzyme 2 (ACE2) expression in diabetic mice (13). 2. OBJECTIVE In this study, we sought to perform a retrospective analysis of metformin and insulin effects in COVID-19 patients with Type 2 Diabetes Mellitus (T2DM). © 2022 Pavlo Petakh,..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit